Fundraising FoxEbvallo
1 known investors
Find your way into Ebvallo
Sign up to see every warm intro you have to Ebvallo
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ebvallo team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EBVALLO is an on-demand allogeneic T-cell immunotherapy for treating relapsed or refractory EBV-positive post-transplant lymphoproliferative disease. The therapy uses anti-EBV-specific cytotoxic T-cells expanded from third-party donors and matched to patient HLA compatibility.
Investors · 1
Frequently asked questions
- What does Ebvallo do?
- EBVALLO is an on-demand allogeneic T-cell immunotherapy for treating relapsed or refractory EBV-positive post-transplant lymphoproliferative disease. The therapy uses anti-EBV-specific cytotoxic T-cells expanded from third-party donors and matched to patient HLA compatibility.
- Who are Ebvallo's investors?
- Ebvallo's investors include HEALTHCARE ROYALTY PARTNERS.